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Abstract 
Background: Systemic lupus erythematosus (SLE) in patients from Spain is associated with intestinal dysbiosis. This 
study explores whether the alteration of the gut microbiome in SLE patients from China is consistent with the intesti-
nal dysbiosis of SLE patients from Spain.
Results: The depletion of Firmicutes and the enrichment of Bacteroidetes in SLE patients from China were consist-
ent with the SLE patients from Spain. Furthermore, we found that nine genera of gut microbiota were SLE-related 
microorganisms in Chinese subjects. Genera Rhodococcus, Eggerthella, Klebsiella, Prevotella, Eubacterium, Flavonifractor 
and Incertae sedis were significantly enriched, while genera Dialister and Pseudobutyrivibrio were significantly depleted 
in SLE patients. Receiver operating characteristic analysis indicated that the nine genera have the potential to distin-
guish SLE patients from healthy controls.
Conclusions: Comparing the dysbiosis of the gut microbiome among SLE patients from China or Spain, may indicate 
that the gut microbiome profiles of SLE patients are more influenced by disease than ethnicity.
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Background
The human gut harbors diverse and abundant microbes 
that benefit us by training the immune system [1], pro-
tecting against opportunistic pathogens [2], and har-
vesting nutrients and energy [3]. Recently, increased 
evidence indicates that intestinal dysbiosis is associated 
with human diseases, such as cancer [4], liver cirrho-
sis [5], and autoimmune diseases [6, 7]. Systemic lupus 
erythematosus (SLE), a complex autoimmune disease 
characterized by its higher frequency in women, is asso-
ciated with the gut microbiome. Compared to healthy 
controls, the SLE patients from Spain were characterized 
by increased Bacteroidetes levels and a lower Firmicutes/
Bacteroidetes ratio [8]. In addition, the species Lactoba-
cillus was applied in management of SLE [9]. Therefore, 
the gut microbiome can serve as new biomarkers or ther-
apy for SLE.
It is well known that the human gut microbiome could 
be susceptible to the host’s genotype [10], age [11], sex 
[12] and diet [13]. The association of the gut microbiome 
with diseases may be diverse due to the above factors. 
For example, the data of the association between the gut 
microbiome and obesity varied in different ethnicities 
[14–16]. The reason may be that pronounced differences 
in the gut microbiome existed among different ethnici-
ties [11]. China and Spain belong to two different con-
tinents with dissimilar genes and diets. Therefore, the 
alterations of the gut microbiome associated with SLE 
should be variable in SLE patients from China versus 
Spain.
In this study, Illumina Miseq sequencing was employed 
to investigate the alterations of the gut microbiome in 
SLE patients from China. The overall goal of the study 
was to ascertain whether the gut microbiome alteration 
of SLE in a Chinese population could be used as a bio-
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Methods
Study subjects
We performed a cross-sectional collection of fecal sam-
ples from female patients diagnosed with SLE from three 
hospitals (Zhejiang Provincial Hospital of TCM, the 
Second Affiliated Hospital of Zhejiang Chinese Medical 
University, and Zhejiang Province People Hospital). The 
diagnosis of SLE was made according to the criteria set 
by the American College of Rheumatology (ACR) [17, 
18]. After the diagnosis, the recruited patients suffered 
from SLE for at least 1  year, did not receive any medi-
cal treatment with 1  month of study participation, and 
had no comorbid disorders. Forty-five female patients 
were included in this study, and their clinical diagnosis 
and blood examination reports were obtained from the 
hospitals. Forty-eight female volunteers were recruited 
by a routine physical examination. The healthy con-
trols had no gastrointestinal tract disorders and did not 
receive antibiotics within 1 month of this study. In addi-
tion, there were no significant differences among the two 
groups in terms of age, smoking history, and alcohol or 
dietary intake. All subjects included in this study pro-
vided written informed consent, and the protocol of this 
study was approved by the Ethics Committee of Zhejiang 
Chinese Medical University. Clinical data such as body 
mass index (BMI), erythrocyte sedimentation rate (ESR), 
SLE disease activity index (SLEDAI) and disease duration 
are shown in Table 1.
Illumina Miseq sequencing of 16S rRNA gene‑based 
amplicons and data processing
Total DNA was extracted from thawed fecal samples 
using the QIAamp® Fast DNA Stool Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer proto-
cols. The V3–V4 regions of the bacterial 16S rRNA gene 
sequences were amplified from the diluted DNA extracts 
with the primers 319F (5′-ACTCCTACGG GAGGC 
AGCAG-3′) and 806R (5′-GGACTACHVGGGTWTC 
TAAT-3′). PCR amplification was performed in a 30  μl 
mixture containing 0.5  μl of DMSO, 1.0  μl of forward 
primer (10 mM), 1.0 μl of reverse primer (10 mM), 5.0 μl 
of DNA sample, 7.5 μl of ddH2O and 15.0 μl of Phusion 
High-Fidelity PCR Master Mix with HF Buffer (NEB). 
The reactions were hot-started at 98 °C for 30 s, followed 
by 30 cycles of 98 °C for 15 s, 58 °C for 15 s, and 72 °C for 
15 s, with a final extension step at 72 °C for 1 min. PCR 
products were purified using a QIAquick Gel Extraction 
kit (Qiagen, Valencia, CA, USA). The amplicon library 
was prepared using a TruSeq™ DNA sample preparation 
kit (Illumina Inc, San Diego, CA). The sequencing reac-
tion was conducted using Illumina MiSeq platforms (Illu-
mina Inc, San Diego, CA).
After sequencing, the data were analyzed on the Quan-
titative Insights Into Microbial Ecology (QIIME, www.
qiime.org) platform using the default parameters [19]. 
Before assembly, sequence reads were first filtered to 
remove low-quality or ambiguous reads, including reads 
lacking exact matching with the primer, reads contain-
ing ambiguous character (N), and reads with an aver-
age quality score <25. Only two reads with a sequence 
overlap longer than 20  bp were assembled. The assem-
bled sequence reads with <400  bp or >500  bp were 
discarded. High-quality sequences were binned into 
16S rRNA Operational Taxonomic Units (OTUs) and 
defined at ≥97% sequence homology. Chimera detec-
tion and removal were assessed using the GOLD refer-
ence databased and uchime [20]. Taxonomic affiliation 
of each OTU was performed with QIIME against the 
SILVA database [21]. Alpha diversity (PD_whole_tree, 
observed species, Simpson, Shannon, Singles, Doubles) 
and beta diversity (unweighted UniFrac) were performed 
in QIIME to 1000 reads, according to the OTU table rar-
efied and 20,000 reads were finally extracted from each 
sample for other analyses.
Statistical analysis
To test whether gut microbial species could be differ-
entiated between SLE patients and healthy controls, a 
metric multidimensional scaling method based on pro-
jection known as principal coordinates analysis (PCoA) 
was used. Each sample was mapped based on the overall 
microbial composition and assessed for similarities.
Table 1 Demographic and clinical chemistry characteristics of human subjects
Characteristics SLE patients Healthy controls
Train Test Train Test
Sample numbers 35 10 35 13
Age mean ± SD [min, max] 46.0 ± 1.8 [25, 61] 39.9 ± 4.3 [18, 62] 43.5 ± 2.4 [22, 68] 42.7 ± 1.9 [20, 56]
BMI (kg/m2) mean ± SD [min, max] 21.5 ± 0.6 [16.4, 28.8] 21.2 ± 1.2 [18.3, 27.7] 22.1 ± 1.0 [20.5, 27.7] 21.6 ± 0.2 [20.6, 25.8]
ESR (mm/h) ± SD [min, max] 14.8 ± 3.3 [3, 38] 14.6 ± 3.9 [8, 46] 6.9 ± 0.6 [4, 15] 7.2 ± 0.4 [3, 12]
SLEDAI ± SD [min, max] 7.5 ± 0.5 [3, 14] 6.7 ± 0.8 [4, 10] – –
Disease duration (years) ± SD [min, max] 7.9 ± 1.2 [1, 28] 5.0 ± 1.6 [1, 16] – –
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Two datasets were created from all study subjects to 
investigate whether microbial biomarkers were available 
for analysis. The first dataset (train) was used to create 
the diagnostic algorithm. The above algorithm was then 
applied to the second dataset (test) for the purpose of 
evaluating how accurately microbial biomarkers were 
identified. All study subjects were randomly and inde-
pendently divided into train or test datasets.
To visualize the potential of significantly altered gen-
era as SLE biomarkers, receiver operating characteristic 
(ROC) curves were plotted in the statistical program-
ming language R (V.3.1.2). ROC curves are an effective 
method of evaluating the quality or performance of diag-
nostic tests and are widely used in gut microbiomes to 
evaluate the performance of many microbial biomarkers. 
Area under the curves (AUCs) of ROC was calculated to 
evaluate the performance of the fitted logistic regression 
models. The AUCs were based on the predicted prob-
ability of SLE for each individual, using the multivariate 
logistic regression coefficient estimates together with the 
individual’s transformed relative abundances for each 
bacterial taxon included in the analysis.
Microbial phylum and genera concentrations between 
SLE patients and healthy controls were compared using a 
Mann–Whitney non-parametric test in SPSS software 16.0.
Results
Structure and composition of the gut microbiome in SLE
To assess overall differences in microbial community 
structure in SLE patients and healthy controls, we calcu-
lated the measures of alpha and beta diversity, represent-
ing microbial diversity in each sample and differences 
among samples, respectively. As shown in Fig. 1, not all 
of the alpha-diversity indices were different. PD_whole_
tree, observed species, Singles and Doubles were signifi-
cantly higher in healthy controls than in SLE patients, 
but there was no difference in Shannon and Simpson. 
The above results indicate that lower diversity, rich-
ness and rare OTUs of gut microbiome existed in SLE 
patients, but the evenness of the gut microbiome could 
not differentiate SLE patients from healthy controls. The 
beta-diversity difference using the weighted UniFrac dis-
tance was shown in PCoA analysis (Fig. 2a). The ordina-
tion plot demonstrated a clear difference between SLE 
patients and healthy controls. Examining shared OTUs 
showed that a total of 4132 OTUs were shared between 
SLE patients and healthy controls, which accounted for 
24.69% of the total OTUs in healthy controls and 40.26% 
of the total OTUs in SLE patients respectively (Fig. 2b).
SLE‑associated microbiota changes
At the phylum level, the gut microbiota of both groups 
was dominated by Firmicutes and Bacteroidetes, which 
contributed to 99% of the gut microbiota, with smaller 
contributions of Proteobacteria, Actinobacteria and 
Fusobacteria. The significantly altered phylum between 
SLE patients and healthy controls is shown in Fig.  3. 
Compared to healthy controls, SLE patients had sig-
nificantly increased relative abundances of the phylum 
Bacteroidetes, Actinobacteria and Proteobacteria and a 
decreased relative abundance of the phylum Firmicutes.
We next investigated whether the relative abundances 
of the gut microbiome differed between SLE patients and 
healthy controls at the genus level (Fig. 3). In the phylum 
Bacteroidetes, only the levels of the genera Prevotella 
were higher in SLE patients than in healthy controls. Five 
significantly altered levels of genera were found in phy-
lum Firmicutes; genera Pseudobutyrivibrio and Dialister 
decreased in SLE patients, while Eubacterium, Flavoni-
fractor, and Incertae sedis increased in SLE patients. Gen-
era Klebsiella of the phylum Proteobacteria was found in 
lower amounts in healthy controls than in SLE patients. 
Genera Rhodococcus and Eggerthella of the phylum Act-
inobacteria were more abundant in SLE patients.
Evaluation of the performance of significantly changed 
genera
To evaluate the utility of the differentially abundant gen-
era as potential biomarkers, we conducted a ROC analy-
sis. Nine significantly altered genera were screened for 
their abilities in distinguishing SLE patients and healthy 
controls. Complete results of train and test validation 
subjects using leave-one-out cross-validation are shown 
in Fig. 4. The combined significantly altered genera have 
the ability to differentiate between SLE patients and 
healthy controls with AUC = 0.960, 95% Cl 0.916–1.0 in 
the train validation subjects and AUC  =  0.923, 95% Cl 
0.813–1.0 in the test validation subjects.
Discussion
The clinical and immunological abnormalities of SLE 
among different ethnicities were known to widely vary 
because of diverse pathogenesis (genetic, environmen-
tal, hormonal, etc.,) [22]. Therefore, the alterations of gut 
microbiome associated with SLE should display differ-
ences among separate ethnicities.
Firstly, a significant depletion of Firmicutes and enrich-
ment of Bacteroidetes in SLE patients were found both 
in Spanish and Chinese subjects. Phylum Firmicutes and 
Bacteroidetes account for more than 90% of all phyloge-
netic species and are involved in host metabolism and 
immunity [1, 23]. Previous studies have described that 
the depletion of Firmicutes and the enrichment of Bac-
teroidetes in the human gut microbiota were associated 
with some disorders [8]. Other studies also showed that 
an altered balance between Bacteroidetes and Firmicutes 
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was correlated with clinical states [24]. Therefore, the 
influence of SLE on human gut microbiome at the phy-
lum level was not characterized by ethnicity. Therefore, 
the disorders of SLE are strongly related to the depletion 
of Firmicutes and the enrichment of Bacteroidetes in 
Spanish and Chinese patients.
Secondly, certain differences in gut microbiome were 
found among SLE patients from Spain and China. At the 
family level, SLE patients from Spain showed a depletion 
of Lachnospiraceae and Ruminococcaceae and an enrich-
ment of Bacteroidaceae and Prevotellaceae [8]. Our study 
indicated that only the family Prevotellaceae showed 
Fig. 1 The alpha-diversity indices between healthy controls and SLE patients from China
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Fig. 2 a PCoA score plots of SLE patients (green) and healthy controls (red) based on the gut microbial composition. b Venn diagrams show the 
percentage of the shared OTUs between SLE patients and healthy controls
Fig. 3 Significantly altered gut microbiota between SLE patients and healthy controls at the phylum and genus levels. “**” denotes p < 0.01, “*” 
denotes p < 0.05. The black column denotes healthy controls, and the blank column denotes SLE patients
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significant increases in SLE patients versus healthy con-
trols from China (data not shown). However, this study 
employed Illumina Miseq sequencing to uncover some 
differences at the genus level between SLE patients and 
healthy controls from China. Significantly altered gen-
era in SLE patients of China were mostly related to the 
intestinal disturbance of autoimmune disorders. Genus 
Rhodococcus infection was observed with Crohn’s dis-
ease [25]. Genera Eggerthella, Klebsiella, Prevotella and 
Dialister were strongly positive for rheumatoid arthri-
tis or ankylosing spondylitis [26–29]. Genus Pseudobu-
tyrivibrio, reduced in SLE patients, displayed decreased 
levels in the gut microbiota profile of psoriatic arthritis 
[30]. Genus Eubacterium was enriched in SLE patients 
of China, but decreased in multiple sclerosis patients 
[31]. The disorders of the gut microbiome at the genera 
level in SLE patients from China were similar to the gut 
microbiome profiles of other autoimmune diseases. Thus, 
a combination of these genera could distinguish SLE 
patients from healthy controls.
As mentioned above, similarities at the phylum level 
and differences at family and genus levels of SLE-related 
gut microbiota existed between Spanish and Chinese 
subjects. The sensitivity of different taxon levels in eval-
uating microbial community may result in the above 
phenomenon. The gut microbiota appears to impose a 
greater influence on the detailed taxon of microorgan-
isms. Therefore, the correlation of SLE with gut micro-
biota at the phylum level was more stable than that at 
the family or genera level. However, the differences of 
SLE-related gut microbiota at family and genera levels 
between Spanish and Chinese populations may be attrib-
uted to the differences of the host’s genetics and diet 
among the two ethnic groups.
Conclusions
Alterations of the gut microbiome in SLE patients from 
China and Spain were shown to be consistent at the phy-
lum level with little differences at the family level. How-
ever, our study further revealed an alteration of the gut 
microbiome in SLE patients at the genus level. Signifi-
cantly altered genera could thus have the ability to dis-
criminate between SLE patients and healthy controls.
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